Details

Autor(en) / Beteiligte

• Funakoshi, Yohei
• Yakushijin, Kimikazu
• Ohji, Goh
• Matsutani, Takaji
• Hojo, Wataru
• Sakai, Hironori
• Matsumoto, Sakuya
• Watanabe, Marika
• Kitao, Akihito
• Saito, Yasuyuki
• Kawamoto, Shinichiro
• Yamamoto, Katsuya
• Koyama, Taiji
• Nagatani, Yoshiaki
• Kimbara, Shiro
• Imamura, Yoshinori
• Kiyota, Naomi
• Ito, Mitsuhiro
• Minami, Hironobu

Titel

Response to mRNA SARS‐CoV‐2 vaccination evaluated by B‐cell receptor repertoire after tixagevimab/cilgavimab administration

Ist Teil von

• British journal of haematology, 2023-08, Vol.202 (3), p.504-516

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• Summary The use of anti‐SARS‐CoV‐2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID‐19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti‐spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS‐CoV‐2 vaccination at the mRNA level using B‐cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV‐AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV‐AbDab clearly demonstrated the response to mRNA SARS‐CoV‐2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation. We have newly established a method to assess the response to mRNA vaccination at the level of mRNA expression (not protein expression). This method uses ‘B‐cell receptor (BCR) repertoire data on the timing of activation of humoral immunity’ and ‘a database of BCR sequences that bind to target antigens’. The method analyses the extent to which antigen‐specific BCR sequences in the database are included in the total BCR sequences obtained from the BCR repertoire analysis.